Table 3

Subgroup analysis for the effect of fibrates therapy on stoke, and fatal stroke
Group Stroke event/total patients Relative risk (RR) P value Heterogeneity P value for heterogeneity
Fibrates Placebo
stroke Published years
after 2000 341/10062 351/10052 0.97 (0.84 to 1.13) 0.72 0% 0.51
before 2000 292/8013 471/9664 1.06 (0.84 to 1.33) 0.63 52% 0.08
Number of patients
≥1000 573/17689 775/19332 0.99 (0.87, 1.12) 0.85 23% 0.26
<1000 60/386 47/384 1.23 (0.80, 1.90) 0.34 30% 0.24
Mean age
<60 32/5331 27/5296 1.18 (0.71 to 1.96) 0.53 - -
≥60 405/11326 439/11319 0.93 (0.80 to 1.08) 0.34 17% 0.30
Gender
male 329/8749 498/10401 1.09 (0.86 to 1.38) 0.47 56% 0.06
Male/female 304/9326 324/9315 0.95 (0.82 to 1.10) 0.48 0% 0.77
Drug
clofibrate 228/6749 383/8397 1.15 (0.98 to 1.34) 0.08 0% 0.59
bezafibrate 132/2331 126/2327 1.05 (0.80 to 1.38) 0.37 21% 0.26
gemfibrozil 64/1335 90/1339 0.72 (0.53 to 0.98) 0.04 0% 0.41
fenofibrate 209/7660 223/7653 0.94 (0.78 to 1.13) 0.49 0% 0.49
Control
corn or olive oil 55/5378 49/5344 1.11 (0.80 to 1.54) 0.53 0% 0.76
placebo 572/12697 761/14372 1.02 (0.88 to 1.17) 0.83 32% 0.17
Follow-up
≥60 months 421/12924 612/14575 1.01 (0.90 to 1.14) 0.85 0% 0.62
<60 months 212/5151 210/5141 1.05 (0.76 to 1.46) 0.75 59% 0.05
Total cholesterol
≥6.0 mmol/L 228/6749 383/8397 1.15 (0.98 to 1.34) 0.08 0% 0.59
<6.0 mmol/L 405/11326 439/11319 0.93 (0.80 to 1.08) 0.34 17% 0.30
Total cholesterol lowering
≥5% 409/12230 586/13890 1.04 (0.92 to 1.18) 0.49 0% 0.51
<5% 173/3080 188/3073 0.98 (0.67 to 1.45) 0.93 71% 0.03
Triglyceride lowering
≥30% 101/1603 113/1603 0.96 (0.46 to 1.99) 0.92 74% 0.02
<30% 477/11094 660/12769 1.02 (0.91 to 1.15) 0.69 0% 0.51
Pre-exsistent diseases
stroke 60/315 45/312 1.28 (0.86 to 1.90) 0.23 35% 0.22
diabetes 209/7660 223/7653 0.94 (0.78 to 1.13) 0.49 0% 0.49
other 364/10100 554/11751 1.00 (0.83 to 1.20) 0.99 36% 0.16
Jadad score
4 481/11575 699/13251 0.95 (0.82 to 1.09) 0.48 30% 0.22
<4 152/6500 123/6465 1.22 (0.98 to 1.52) 0.07 0% 0.58
Overall 633/18075 822/19716 1.02 (0.90 to 1.16) 0.78 27% 0.20
Fatal stroke Published years
after 2000 17/3548 17/3538 0.93 (0.33 to 2.60) 0.89 51% 0.15
before 2000 24/6910 35/6875 0.70 (0.41 to 1.19) 0.18 0% 0.47
Number of patients
≥1000 34/10143 40/10101 0.82 (0.45 to 1.48) 0.51 32% 0.22
<1000 7/315 12/312 0.59 (0.23 to 1.47) 0.26 0% 0.59
Mean age
<60 14/5331 14/5296 0.99 (0.47 to 2.08) 0.99 - -
≥60 20/4812 26/4805 0.69 (0.27 to 1.75) 0.44 53% 0.12
Gender
male 35/7646 39/7612 0.89 (0.53 to 1.51) 0.67 19% 0.30
Male/female 6/2812 13/2801 0.46 (0.18 to 1.21) 0.12 0% 0.85
Drug
clofibrate 21/5646 26/5608 0.81 (0.45 to 1.44) 0.47 0% 0.59
bezafibrate 13/783 9/785 1.45 (0.62 to 3.37) 0.39 - -
gemfibrozil 3/1264 9/1267 0.33 (0.09 to 1.23) 0.10 - -
fenofibrate 4/2765 8/2753 0.50 (0.15 to 1.65) 0.25 - -
Control
corn or olive oil 16/5378 19/5344 0.85 (0.43 to 1.66) 0.63 0% 0.32
placebo 25/5151 33/5141 0.73 (0.38 to 1.40) 0.34 30% 0.23
Follow-up
≥60 months 16/5378 19/5344 0.85 (0.43 to 1.66) 0.63 0% 0.32
<60 months 25/5080 33/5069 0.73 (0.38 to 1.40) 0.34 30% 0.23
Total cholesterol
≥6.0 mmol/L 21/5646 26/5608 0.81 (0.45 to 1.44) 0.47 0% 0.59
<6.0 mmol/L 20/4812 26/4805 0.69 (0.27 to 1.75) 0.44 53% 0.12
Total cholesterol lowering
≥5% 29/6161 28/6129 1.04 (0.62 to 1.76) 0.87 0% 0.38
<5% 8/1532 16/1531 0.51 (0.22 to 1.20) 0.12 0% 0.40
Triglyceride lowering
≥30% 8/1532 16/1531 0.51 (0.22 to 1.20) 0.12 0% 0.40
<30% 17/3548 17/3538 0.93 (0.33 to 2.60) 0.89 51% 0.15
Pre-exsistent diseases
stroke 7/315 12/312 0.59 (0.23 to 1.47) 0.26 0% 0.59
diabetes 4/2765 8/2753 0.50 (0.15 to 1.65) 0.25 - -
other 30/7378 32/7348 0.91 (0.45 to 1.83) 0.78 42% 0.18
Jadad score
4 7/4029 17/4020 0.41 (0.17 to 1.00) 0.05 0% 0.66
<4 34/6429 35/6393 0.97 (0.60 to 1.57) 0.91 0% 0.51
Overall 41/10458 52/10413 0.79 (0.51 to 1.23) 0.30 6% 0.38

Zhou et al.

Zhou et al. BMC Neurology 2013 13:1   doi:10.1186/1471-2377-13-1

Open Data